<unk>  is now recommended as first-line treatment for tuberculosis (TB), but rifampicin was used more widely because of its cheaper cost. However, due to the expiration of patents, prices are now similar.<unk>  is also used in the treatment of Mycobacterium avium complex disease, a bacterial infection most commonly encountered in people with late-stage AIDS. Its has fewer drug interactions than rifampicin, therefore people with HIV/AIDS on HAART are typically prescribed<unk>  instead of rifampicin for the treatment of TB.<unk>  is well-tolerated in people with HIV-related TB, but new findings suggest that those with low CD4+ cell counts have a higher risk of treatment failure or relapse due to acquired rifamycin resistance. Since patients co-infected with TB and HIV are likely to be treated for TB first, when the CD4+ cell population is depressed at the time TB treatment begins, doctors and patients should be aware of the possibility for rifamycin resistance to develop. Rifamycins, including<unk> , are useful in the treatment of Chlamydophila pneumoniae (Cpn) infection.<unk>  is being tested in clinical trials for treating Crohn's disease as part of the anti-MAP therapy. In a Phase III study administering sub-therapeutic doses of<unk>  in combination therapy to patients not identified with MAP infections, it was associated with significant short term benefits.<unk>  is also being investigated for the treatment of infections caused by the Gram-negative bacillus Acinetobacter baumannii, which has shown promise in animal studies.
Rifabutin
Pyrazinamide
Delamanid
Safinamide
Amifampridine
Deoxygedunin
Miproxifene phosphate
Rifampicin